

AlÃ- Duarte-GarcÃ-a

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8018663/publications.pdf>

Version: 2024-02-01

52
papers

1,641
citations

394421
19
h-index

315739
38
g-index

52
all docs

52
docs citations

52
times ranked

2398
citing authors

#	ARTICLE	IF	CITATIONS
1	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. <i>Annals of Internal Medicine</i> , 2020, 172, 819-821.	3.9	177
2	The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 1545-1552.	5.6	172
3	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
4	<scp>SARS</scp>â€“<scp>CoV</scp>â€“2 Infection and <scp>COVID</scp>â€“19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 766-775.	5.6	117
5	Antiphospholipid Syndrome. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2317-2330.	2.8	109
6	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
7	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	1.6	80
8	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 659-666.	3.0	57
9	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 36-47.	5.6	52
10	Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2020, 72, 733-749.	5.6	51
11	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.9	49
12	Epidemiology of Antiphospholipid Syndrome in the General Population. <i>Current Rheumatology Reports</i> , 2021, 23, 85.	4.7	49
13	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	2.0	36
14	<i>Festina lente</i>: hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 734-736.	0.9	35
15	Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 861-867.	0.9	35
16	The Evidence Basis for the American College of Rheumatology Practice Guidelines. <i>JAMA Internal Medicine</i> , 2018, 178, 146.	5.1	33
17	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	3.9	30
18	Diagnostic Delay in Psoriatic Arthritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2021, 48, 1410-1416.	2.0	25

#	ARTICLE	IF	CITATIONS
19	The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population-Based Study. Arthritis and Rheumatology, 2021, 73, 1878-1885.	5.6	25
20	Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. Annals of the Rheumatic Diseases, 2022, 81, 1260-1266.	0.9	23
21	Industry Payments to Practicing US Rheumatologists, 2014-2019. Arthritis and Rheumatology, 2021, 73, 2138-2144.	5.6	22
22	Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with Systemic Lupus Erythematosus and Cognitive Dysfunction. PLoS ONE, 2018, 13, e0196487.	2.5	21
23	Predictors of incident proteinuria among patients with SLE. Lupus Science and Medicine, 2017, 4, e000200.	2.7	19
24	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Seminars in Arthritis and Rheumatism, 2020, 50, 1191-1201.	3.4	19
25	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. Frontiers in Immunology, 2022, 13, 834981.	4.8	19
26	Effect of omega-3 fatty acids on systemic lupus erythematosus disease activity: A systematic review and meta-analysis. Autoimmunity Reviews, 2020, 19, 102688.	5.8	17
27	Disease progression of Takayasu arteritis in two patients treated with tocilizumab. Annals of the Rheumatic Diseases, 2020, 79, e21-e21.	0.9	15
28	Effect of statin use on the risk of rheumatoid arthritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2020, 50, 1348-1356.	3.4	13
29	Population-based incidence and time to classification of systemic lupus erythematosus by three different classification criteria: a Lupus Midwest Network (LUMEN) study. Rheumatology, 2022, 61, 2424-2431.	1.9	12
30	Measuring Outcomes in Axial Spondyloarthritis. Arthritis Care and Research, 2020, 72, 47-71.	3.4	11
31	Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. Mayo Clinic Proceedings, 2022, 97, 250-260.	3.0	10
32	The protective effect of rheumatic disease agents in COVID-19. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101659.	3.3	9
33	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. Journal of Rheumatology, 2022, 49, 110-114.	2.0	9
34	Older Drugs With Limited Trial Evidence: Are They Worth the Expense? The Case of Repository Corticotropin Marketed as H.P. Acthar Gel. Annals of Internal Medicine, 2019, 170, 791.	3.9	9
35	Treatment of thrombotic antiphospholipid syndrome in adults and children. Current Opinion in Rheumatology, 2020, 32, 215-227.	4.3	8
36	Systematic Appraisal of the American College of Rheumatology Clinical Practice Guidelines. ACR Open Rheumatology, 2019, 1, 188-193.	2.1	7

#	ARTICLE	IF	CITATIONS
37	Epidemiology of <sc>Childhoodâ€Onset</sc> Systemic Lupus Erythematosus: A <sc>Populationâ€Based</sc> Study. Arthritis Care and Research, 2022, 74, 728-732.	3.4	7
38	Time to transition from psoriasis to psoriatic arthritis: A population-based study. Seminars in Arthritis and Rheumatism, 2022, 52, 151949.	3.4	6
39	Risk of hydroxychloroquine retinopathy in the community. Rheumatology, 2022, 61, 3172-3179.	1.9	5
40	Older Drugs With Limited Trial Evidence: Are They Worth the Expense?. Annals of Internal Medicine, 2019, 171, 602.	3.9	3
41	Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS. Rheumatology, 2022, 61, 4962-4974.	1.9	3
42	Response to: â€Correspondence on â€Festina lente</i>: hydroxychloroquine, COVID-19and the role of the rheumatologistâ€™ by Graef<i>et al</i>â€™ by Lo<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e164-e164.	0.9	2
43	Striatal Encephalitis: Potential Inflammatory Vasculopathy in Systemic Lupus Erythematosus. Canadian Journal of Neurological Sciences, 2021, 48, 415-416.	0.5	2
44	28-Year-Old Woman With Chronic Kidney Disease, Fatigue, and Polyarthralgias. Mayo Clinic Proceedings, 2021, 96, 231-236.	3.0	1
45	Reply. Arthritis and Rheumatology, 2019, 71, 1769-1770.	5.6	0
46	Reply. Arthritis and Rheumatology, 2020, 72, 2164-2165.	5.6	0
47	Reply. Arthritis and Rheumatology, 2020, 72, 1776-1776.	5.6	0
48	28-Year-Old Man With Recurrent Vertigo, Syncope, and Progressive Memory Impairment. Mayo Clinic Proceedings, 2021, 96, 1309-1314.	3.0	0
49	Reply. Arthritis and Rheumatology, 2021, 73, 1767-1768.	5.6	0
50	Characteristics of Hydroxychloroquine Dispensing in the United States, January to May 2020. Journal of General Internal Medicine, 2021, , 1.	2.6	0
51	75-Year-Old Man With Fever and Malaise. Mayo Clinic Proceedings, 2021, 96, 2905-2910.	3.0	0
52	Industry involvement in rheumatology consensus-based recommendations: a systematic review. Lancet Rheumatology, The, 2022, 4, e145-e152.	3.9	0